Jantikar A, Brashier B, Maganji M, Raghupathy A, Mahadik P, Gokhale P, Gogtay J, Salvi S
Chest Research Foundation, Marigold Premises, Survey No. 15, Vadgaonsheri, Kalyaninagar, Pune 411014, India.
Respir Med. 2007 Apr;101(4):845-9. doi: 10.1016/j.rmed.2006.02.020. Epub 2007 Feb 1.
Salbutamol, the most widely used short-acting beta(2)-agonist, consists of a racemic mixture of equal amounts of two enantiomers, (R)-salbutamol and (S)-salbutamol. The bronchodilator effects of salbutamol are attributed entirely to (R)-salbutamol (levosalbutamol), while (S)-salbutamol has been shown to possess bronchospastic and pro-inflammatory effects both in vitro and in vivo studies. Levosalbutamol, the (R)-enantiomer of salbutamol is currently available only in a liquid formulation for use via a nebulizer. Recently, levosalbutamol to be administered via a pressurized metered dose inhaler (pMDI) has been developed.
To compare the time-dependent bronchodilator responses of single doses of 100mcg levosalbutamol and 200 mcg racemic salbutamol administered via a pMDI in subjects with stable mild-to-moderate bronchial asthma over a period of 6h.
Single doses of 100 mcg levosalbutamol, 200 mcg salbutamol and placebo were administered with a pMDI in 30 stable asthmatic subjects in a randomized, double-blind, placebo-controlled, three-way cross over study. Forced expiratory volume in 1s (FEV(1)) and forced vital capacity (FVC) were measured at baseline, and over 6h post-study drug administration.
Levosalbutamol and salbutamol produced significantly better bronchodilator responses than placebo. Both the drugs showed equivalent time-dependent bronchodilator responses as measured by area under curve for percent change in FEV(1) and FVC over 6h. The time to onset of action, mean maximum bronchodilator response and duration of bronchodilator response were similar between levosalbutamol and salbutamol.
A single dose of 100 mcg levosalbutamol administered by a pMDI produced a similar bronchodilator response as salbutamol when measured over 6h in subjects with stable, mild-to-moderate bronchial asthma.
沙丁胺醇是使用最广泛的短效β₂受体激动剂,由等量的两种对映体(R)-沙丁胺醇和(S)-沙丁胺醇的外消旋混合物组成。沙丁胺醇的支气管扩张作用完全归因于(R)-沙丁胺醇(左沙丁胺醇),而在体外和体内研究中,(S)-沙丁胺醇已被证明具有支气管痉挛和促炎作用。左沙丁胺醇,即沙丁胺醇的(R)-对映体,目前仅有液体制剂,通过雾化器使用。最近,已开发出可通过压力定量吸入器(pMDI)给药的左沙丁胺醇。
比较在6小时内,通过pMDI给稳定的轻至中度支气管哮喘患者单次给予100μg左沙丁胺醇和200μg消旋沙丁胺醇后,随时间变化的支气管扩张反应。
在一项随机、双盲、安慰剂对照、三向交叉研究中,用pMDI给30名稳定的哮喘患者单次给予100μg左沙丁胺醇、200μg沙丁胺醇和安慰剂。在基线以及研究药物给药后6小时内测量第1秒用力呼气容积(FEV₁)和用力肺活量(FVC)。
左沙丁胺醇和沙丁胺醇产生的支气管扩张反应明显优于安慰剂。通过6小时内FEV₁和FVC变化百分比的曲线下面积测量,两种药物显示出等效的随时间变化的支气管扩张反应。左沙丁胺醇和沙丁胺醇之间的起效时间、平均最大支气管扩张反应和支气管扩张反应持续时间相似。
在稳定的轻至中度支气管哮喘患者中,通过pMDI单次给予100μg左沙丁胺醇,在6小时测量时产生的支气管扩张反应与沙丁胺醇相似。